Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 RadNetRenalytix AIPersonalisDermTechCastle Biosciences
SymbolNASDAQ:RDNTNASDAQ:RNLXNASDAQ:PSNLNASDAQ:DMTKNASDAQ:CSTL
Price Information
Current Price$21.37$24.57$23.02$48.60$69.51
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.50.61.81.61.7
Analysis Score2.51.24.42.52.5
Community Score2.61.22.73.12.9
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.72.5
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$24.50$22.00$40.56$56.75$83.20
% Upside from Price Target14.65% upside-10.46% downside76.18% upside16.77% upside19.70% upside
Trade Information
Market Cap$1.12 billion$885.11 million$1.01 billion$1.40 billion$1.74 billion
Beta1.52N/A1.710.990.46
Average Volume202,736136,0921,089,3971,518,029315,923
Sales & Book Value
Annual Revenue$1.15 billionN/A$65.21 million$3.36 million$51.87 million
Price / Sales0.97N/A15.45415.9433.47
Cashflow$3.35 per shareN/AN/AN/A$0.13 per share
Price / Cash6.38N/AN/AN/A539.36
Book Value$4.63 per share$0.45 per share$3.42 per share$1.01 per share$4.98 per share
Price / Book4.62N/A6.7348.1213.96
Profitability
Net Income$14.76 million$-9,840,000.00$-25,080,000.00$-19,690,000.00$5.28 million
EPS$0.29($0.16)($1.39)($2.81)($0.81)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E Ratio46.461,228.50N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-0.98%N/A-45.13%-577.75%-5.30%
Return on Equity (ROE)-2.72%N/A-27.53%-65.00%-2.69%
Return on Assets (ROA)-0.37%N/A-19.66%-58.37%-2.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.55%N/AN/AN/A0.07%
Current Ratio0.69%22.75%6.23%13.31%6.65%
Quick Ratio0.69%22.75%6.05%13.28%6.59%
Ownership Information
Institutional Ownership Percentage67.46%13.61%65.46%51.35%66.42%
Insider Ownership Percentage5.77%N/A8.20%16.48%39.70%
Miscellaneous
Employees6,1658234114199
Shares Outstanding52.27 million36.02 million43.77 million28.76 million24.98 million
Next Earnings Date5/10/2021 (Estimated)N/A5/6/2021 (Estimated)N/A5/10/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $73.39Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $73.39
americanbankingnews.com - April 6 at 11:00 AM
Castle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading VolumeCastle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading Volume
americanbankingnews.com - April 1 at 12:08 PM
Castle Biosciences Collaborates with the Melanoma Research Foundation for "Ask the Expert” Live Webinar Series with Melanoma ExpertsCastle Biosciences Collaborates with the Melanoma Research Foundation for "Ask the Expert” Live Webinar Series with Melanoma Experts
markets.businessinsider.com - April 1 at 8:54 AM
Castle Biosciences Collaborates with the Melanoma Research Foundation for "Ask the Expert" Live Webinar Series with Melanoma ExpertsCastle Biosciences Collaborates with the Melanoma Research Foundation for "Ask the Expert" Live Webinar Series with Melanoma Experts
finance.yahoo.com - April 1 at 8:54 AM
Castle Biosciences (NASDAQ:CSTL) Trading Up 7.1%Castle Biosciences (NASDAQ:CSTL) Trading Up 7.1%
americanbankingnews.com - March 31 at 12:00 PM
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 13,275 Shares of StockInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 13,275 Shares of Stock
americanbankingnews.com - March 30 at 8:00 PM
Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare ConferenceCastle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - March 29 at 7:55 PM
Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical ManagemeCastle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Manageme
us.acrofan.com - March 25 at 9:34 PM
Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management DecisionsCastle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions
finance.yahoo.com - March 25 at 9:34 PM
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells 10,000 Shares of StockInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells 10,000 Shares of Stock
americanbankingnews.com - March 23 at 7:40 PM
David S. Kabakoff Sells 10,000 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockDavid S. Kabakoff Sells 10,000 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock
americanbankingnews.com - March 23 at 7:40 PM
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of "Buy" by BrokeragesCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of "Buy" by Brokerages
americanbankingnews.com - March 22 at 5:16 PM
Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Zacks Investment ResearchCastle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Zacks Investment Research
marketbeat.com - March 11 at 7:39 PM
Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last?Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last?
finance.yahoo.com - March 11 at 8:34 AM
Heres What Analysts Are Forecasting For Castle Biosciences, Inc. (NASDAQ:CSTL) After Its Yearly ResultsHere's What Analysts Are Forecasting For Castle Biosciences, Inc. (NASDAQ:CSTL) After Its Yearly Results
nasdaq.com - March 10 at 9:26 AM
Castle Biosciences Sinks 6% On Wider-Than-Expected 4Q Loss, Sales Top EstimatesCastle Biosciences Sinks 6% On Wider-Than-Expected 4Q Loss, Sales Top Estimates
finance.yahoo.com - March 9 at 8:23 AM
Castle Biosciences: Q4 Earnings InsightsCastle Biosciences: Q4 Earnings Insights
finance.yahoo.com - March 8 at 10:06 PM
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue EstimatesCastle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 8 at 10:06 PM
Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized RiskCastle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
finance.yahoo.com - March 8 at 5:05 PM
Castle Biosciences Announces Fourth Quarter and Full-Year 2020 ResultsCastle Biosciences Announces Fourth Quarter and Full-Year 2020 Results
finance.yahoo.com - March 8 at 5:05 PM
Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season?Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season?
finance.yahoo.com - March 5 at 9:56 AM
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - March 1 at 6:29 PM
Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021
finance.yahoo.com - February 22 at 9:33 AM
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th AnnCastle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Ann
us.acrofan.com - February 4 at 8:23 AM
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach SymposiumCastle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
finance.yahoo.com - February 4 at 8:23 AM
An Intrinsic Calculation For Castle Biosciences, Inc. (NASDAQ:CSTL) Suggests Its 41% UndervaluedAn Intrinsic Calculation For Castle Biosciences, Inc. (NASDAQ:CSTL) Suggests It's 41% Undervalued
finance.yahoo.com - February 1 at 9:27 AM
DateCompanyBrokerageAction
3/15/2021RadNetRaymond JamesBoost Price Target
5/26/2020RadNetSidotiBoost Price Target
3/2/2021Renalytix AIInvestecDowngrade
8/11/2020Renalytix AIJPMorgan Chase & Co.Initiated Coverage
8/11/2020Renalytix AIStifel NicolausInitiated Coverage
3/8/2021PersonalisMorgan StanleyBoost Price Target
3/4/2021PersonalisNeedham & Company LLCReiterated Rating
1/27/2021PersonalisTruistInitiated Coverage
1/13/2021PersonalisHC WainwrightBoost Price Target
1/12/2021PersonalisOppenheimerReiterated Rating
1/4/2021PersonalisBank of AmericaDowngrade
12/16/2020PersonalisCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/16/2020PersonalisSmith Barney CitigroupBoost Price Target
10/7/2020PersonalisBTIG ResearchInitiated Coverage
3/5/2021DermTechCraig HallumBoost Price Target
2/11/2021DermTechLake Street CapitalBoost Price Target
10/29/2020DermTechWilliam BlairInitiated Coverage
9/11/2020DermTechBrookline Capital ManagementInitiated Coverage
9/10/2020DermTechCowenInitiated Coverage
3/9/2021Castle BiosciencesRobert W. BairdLower Price Target
2/3/2021Castle BiosciencesKeyCorpBoost Price Target
1/26/2021Castle BiosciencesCanaccord GenuityBoost Price Target
1/15/2021Castle BiosciencesSVB LeerinkBoost Price Target
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.